Immunotherapy plus radiation trial for head and neck cancer halted early

NCT ID NCT03386357

First seen Apr 08, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tested whether adding radiation to the immunotherapy drug pembrolizumab could help control metastatic head and neck cancer that had already been treated once. It was designed for adults with at least two tumors, one of which would receive radiation. The trial was terminated early, so final results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bochum, St. Josef-Hospital, Abteilung für Hämatologie und Onkologie

    Bochum, 44791, Germany

  • Dresden, Onkologische Gemeinschaftspraxis

    Dresden, 01307, Germany

  • Düsseldorf, Universitätsklinikum, Klinik für Strahlentherrapie und Radiologische Onkologie

    Düsseldorf, 40225, Germany

  • Erlangen, Universitätsklinikum Strahlenklinik

    Erlangen, 91054, Germany

  • Frankfurt, Universitätsklinikum, Klinik für Strahlentherapie und Onkologie

    Frankfurt, 60590, Germany

  • Homburg, Universitätsklinikum, Klinik für Strahlentherapie und Radioonkologie

    Homburg, 66421, Germany

  • Regensburg, Universitätsklinikum, Klinik für Strahlentherapie

    Regensburg, 93042, Germany

Conditions

Explore the condition pages connected to this study.